POTS, MCAS, and the EDS Triad

Table of Contents

  1. What the Triad Is
  2. The Numbers: How Often These Conditions Cluster
  3. Why They Cluster: The Connective-Tissue Hypothesis
  4. Beyond the Triad: The Pentad
  5. What POTS Looks Like in an hEDS Body
  6. What MCAS Looks Like in an hEDS Body
  7. The Right Workup Order
  8. What to Test — and Where
  9. Treatment Ordering — Stabilize First, Medicate Second
  10. Medications That Actually Help
  11. The “Floppy Valve” Rule-Out
  12. Eosinophilic GI Disorders in the Triad
  13. The Tethered Cord Debate
  14. Self-Advocacy — The One-Page Summary
  15. The Psychological Weight
  16. When You Still Hear “It’s All in Your Head”
  17. Key Research Papers
  18. Research Papers
  19. Connections

What the Triad Is

The “EDS triad” is a pattern, not a formal diagnosis. For decades, rheumatologists, cardiologists, and allergists noticed that a striking share of their hypermobile Ehlers-Danlos (hEDS) and hypermobility-spectrum-disorder (HSD) patients also had Postural Orthostatic Tachycardia Syndrome (POTS) and Mast Cell Activation Syndrome (MCAS). Put differently: a bendy person who faints when they stand up and breaks out in hives after a steak dinner is not a coincidence. It is, statistically, a type.

The three conditions are now recognized as a comorbidity cluster that behaves almost like a single multi-system disease. You can have one of the three. You can have two. And a meaningful minority have all three, often diagnosed years apart after being bounced between specialists who each saw their corner of the problem.

If you are reading this because a doctor finally said the word “triad” and you felt a decade of scattered symptoms snap into focus — you are not alone. That experience is the rule.

The Numbers: How Often These Conditions Cluster

The estimates vary by cohort and how strictly each condition is defined, but the signal is consistent:

These numbers are not small-study noise. They appear in dedicated hypermobility clinics across the US, UK, Spain, and Italy. Whatever is going on, it is not rare, and it is not random.

Why They Cluster: The Connective-Tissue Hypothesis

Nobody has the final answer, but four mechanisms show up in the literature repeatedly, and they probably all contribute.

1. Over-compliant vessels. Your blood vessels are lined with connective tissue. In hEDS, that tissue is measurably stretchier. When you stand up, more blood pools in the veins of your legs and abdomen than it should. Less blood returns to the heart. Your heart rate races to compensate. That is textbook POTS — but driven by a structural, connective-tissue cause rather than a primary autonomic one.

2. Mast cells live in connective tissue. Mast cells are immune cells that release histamine, tryptase, prostaglandins, and dozens of other mediators. They are densest in the skin, gut lining, airways, and perivascular spaces — every tissue that is also rich in collagen. Work by Bonamichi-Santos and colleagues (2018) suggests that the same connective-tissue milieu that misbehaves in hEDS may destabilize the mast cells that live inside it, lowering their activation threshold.

3. Shared genetic susceptibility. Hypermobile EDS does not have a confirmed gene yet, but family clustering is obvious — and POTS and MCAS run in the same families. Whatever gene (or set of genes) underlies hEDS very likely overlaps with the autonomic and mast-cell pathways.

4. Autonomic dysfunction feeds back. A dysregulated autonomic nervous system can directly trigger mast cell degranulation (through substance P, CRH, and other neuropeptides). Mast cell mediators in turn affect vascular tone and heart rate. The triad is not three parallel problems — it is a loop, and kicking any one leg of it makes the others worse.

Beyond the Triad: The Pentad

Some clinicians (notably at The EDS Society’s research collaborations) now describe a pentad — the triad plus two additional categories:

The pentad is a useful clinical shorthand, though not everyone accepts it as a formal unit. If you have hEDS plus POTS plus MCAS plus swallowing problems plus a history of Chiari-like headaches, knowing the pentad exists can save you years of fragmented workup.

What POTS Looks Like in an hEDS Body

Classic POTS is a sustained heart-rate rise of ≥30 bpm within 10 minutes of standing (≥40 bpm in adolescents) without a drop in blood pressure. In an hEDS patient, the story usually includes:

The hEDS version of POTS often includes a prominent venous pooling picture — visibly dusky legs, compression garments feel transformative, and fluid loading helps more than it does in other POTS subtypes. See the POTS overview and the POTS/MCAS/EDS triad deep dive from the POTS side for the full subtype discussion.

What MCAS Looks Like in an hEDS Body

MCAS is harder to pin down because mast cells release so many different mediators and every patient’s pattern is slightly different. Common features:

The MCAS story in hEDS is usually “I react to everything, but never the same thing twice.” Standard allergy testing is negative. Patients get written off as anxious or “sensitive.” For a deep dive on what mast cells actually release and which organ each mediator hits, see the MCAS mediators and symptom map.

The Right Workup Order

The single most common mistake in triad care is doing the three workups in the wrong order. The order that actually works:

  1. Establish hEDS or HSD first. Use the 2017 International Criteria (Beighton score, systemic features, family history, exclusion of other heritable connective tissue disorders). See the hEDS 2017 criteria article.
  2. Rule out structural heart disease with an echocardiogram — specifically looking at the mitral valve and aortic root (see the floppy valve section).
  3. Test for orthostatic intolerance. Start with the NASA 10-minute lean test at home (cheap, reproducible) and escalate to a formal tilt-table study if needed.
  4. Evaluate MCAS last, because it is the hardest to confirm biochemically and the most likely to be dismissed before the structural pieces are in place.

Doing it in this order stops you from chasing an MCAS diagnosis while an undetected aortic root issue or a correctable volume-depletion problem dominates your symptoms.

What to Test — and Where

For POTS:

For MCAS:

For a step-by-step on which lab runs what panel and how to avoid common collection errors, see the MCAS testing guide.

Treatment Ordering — Stabilize First, Medicate Second

The most important principle in triad treatment is boring and non-pharmaceutical: stabilize the joints first. Every unbraced subluxation fires pain signals, triggers autonomic stress, and in many patients triggers mast cell degranulation. Patients who jump straight to beta-blockers or H1/H2 blockers without getting their joints supported usually stall out.

The ordering that gets people back to functional lives:

  1. EDS stabilization. Targeted physical therapy (isometric-first, low-load, proprioception-heavy), bracing for unstable joints, pacing education. See the PT and joint protection article.
  2. POTS volume loading. Target 3–4 liters of fluid per day, 8–12 grams of sodium per day (unless you have a reason not to), 20–30 mmHg graduated waist-high compression, elevated head of bed, recumbent exercise (rower, recumbent bike, swimming) ramped gradually.
  3. MCAS foundations. Low-histamine diet trial, avoid obvious mediator triggers, H1 and H2 blockers daily (not as needed), and a mast cell stabilizer if needed (cromolyn, ketotifen).
  4. Then, and only then, escalating medications for whichever leg of the triad is still the dominant problem.

Skipping steps does not save time. It almost always wastes a year.

Medications That Actually Help

For POTS:

For MCAS:

The “Floppy Valve” Rule-Out

Mitral valve prolapse is more common in hEDS — the same collagen defect makes the valve leaflets slightly redundant. Most MVP is benign, but it can cause palpitations, atypical chest pain, and presyncope that mimic POTS exactly. Aortic root dilation, though much more characteristic of vascular EDS, can also occur in hEDS in a minority of cases.

Get one good transthoracic echocardiogram during the workup. If normal, you probably do not need another for years unless symptoms change. If abnormal, you have redirected your entire treatment algorithm for the better.

Eosinophilic GI Disorders in the Triad

If you have triad symptoms plus trouble swallowing solid food, food impactions, persistent reflux unresponsive to PPIs, or chronic upper-abdominal pain, ask for an upper endoscopy with biopsies specifically counting eosinophils per high-power field. Eosinophilic esophagitis is defined as ≥15 eos/hpf. It is frequently missed because standard reflux biopsies do not count eosinophils unless explicitly requested.

EoE responds well to swallowed topical corticosteroids (budesonide slurry or fluticasone) and to a six-food elimination diet. Treating it often unwinds a large piece of what looks like MCAS.

The Tethered Cord Debate

A minority of hEDS patients present with lower-back pain, urinary urgency, leg weakness, and autonomic symptoms that turn out to correlate with MRI evidence of a low-lying conus medullaris or thickened filum terminale — tethered cord syndrome. A smaller number have craniocervical instability or Chiari I malformation.

Here the literature and the neurosurgical community split. Some centers perform detethering surgery with reported benefit in select patients. Other centers consider the radiographic findings over-called and the surgical outcomes inadequately studied. If you are considering neurosurgical intervention: get at least two opinions at high-volume EDS centers, insist on dynamic imaging (flexion/extension MRI, upright MRI if available), and be cautious of any center that recommends surgery at a first visit without functional testing. This is a legitimate but still-contested area of triad medicine.

Self-Advocacy — The One-Page Summary

The average triad patient spends 10 to 15 years seeing specialists before anyone connects the three conditions. Every new appointment starts from zero. The single most useful tool you can build is a one-page summary that you hand to every new doctor in the first 30 seconds of the visit.

Include on one page, in this order:

  1. Your diagnoses, in bold, with dates and the clinician who made each one.
  2. Beighton score, key hEDS systemic features.
  3. Active-stand or tilt-table results (HR rise and BP pattern).
  4. Tryptase baseline and flare values if you have them; any positive urine mediators.
  5. Current medications and doses (list what has failed, not just what works).
  6. Allergies and medications to avoid (especially opiates, NSAID issues, contrast reactions).
  7. Your single most important question for this visit.

Hand it over. Say: “This is my summary. Can we start from here?” It changes the visit. It also protects you on days when brain fog makes it hard to explain your own history from scratch.

The Psychological Weight

Anxiety and depression are measurably elevated in triad patients, and not because the patients are weak. Living in a body whose heart rate, skin, and gut can all go sideways without warning is genuinely destabilizing. The autonomic dysregulation itself produces feelings that are physiologically indistinguishable from panic attacks. Mast cell mediators cross the blood-brain barrier and contribute to mood symptoms.

Treatment that helps:

When You Still Hear “It’s All in Your Head”

Despite the growing literature, triad patients still routinely hear it. What to do:

You are not imagining this. You have a pattern with a name, a literature, and increasingly effective treatments. Finding clinicians who see it is the work; the work is worth doing.

Key Research Papers

Research Papers

The following PubMed topic searches return current peer-reviewed work on the POTS/MCAS/hEDS cluster:

  1. Hypermobile EDS with POTS and MCAS
  2. Ehlers-Danlos and postural orthostatic tachycardia
  3. Mast cell activation syndrome and hypermobility
  4. hEDS and autonomic dysfunction
  5. Hereditary alpha-tryptasemia and TPSAB1 copy number
  6. Eosinophilic esophagitis and connective tissue disorders
  7. Tethered cord syndrome and Ehlers-Danlos
  8. Ivabradine in POTS and hypermobility
  9. Low-dose naltrexone and mast cell modulation

Connections

Back to Table of Contents